Plus Therapeutics Secures Humana Coverage for CNS Cancer Assay
The agreement extends CNSide cerebrospinal fluid test coverage to 16 million additional patients nationwide.
The agreement extends CNSide cerebrospinal fluid test coverage to 16 million additional patients nationwide.
The deep learning system integrates dermoscopic images with patient metadata to improve diagnostic precision for skin cancer screening.
UCLA Health researchers find cell-free DNA combined with machine learning can distinguish ALS from other neurological conditions.
Research demonstrates 13% relative reduction in prostate cancer deaths but highlights overdiagnosis concerns, prompting calls for risk-based screening approaches.
Sample-to-answer assay delivers results in approximately 45 minutes from nasopharyngeal and nasal swab specimens.
Researchers urge clinicians to integrate lipid management into prenatal care to mitigate elevated obstetric complications and cardiovascular risks.
The multiplex immunoassay measures autoantibodies to the 14-3-3eta protein and aims to reduce diagnostic delays that currently average seven to 10 years.
The quantitative measurement test is designed to aid in myocardial infarction diagnosis using human plasma samples.
The validation enables its use as a blood-based biomarker for inclusion and exclusion in clinical trials in both the United States and Europe.
The automated system uses ion exchange HPLC technology to deliver A1c results while detecting common hemoglobin variants.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
TriVerity system demonstrated high sensitivity and specificity across more than 1,200 patients in pivotal SEPSIS-SHIELD trial.